• Profile
Close

Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial

JAMA Psychiatry Jan 05, 2018

Daly EJ, et al. - The efficacy, safety, and dose-response of intranasal esketamine hydrochloride were evaluated in patients with treatment-resistant depression (TRD). The antidepressant effect was found to be rapid in onset and dose related. With a lower dosing frequency, the response appeared to persist for more than 2 months. The outcomes supported additional investigation in larger trials.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay